Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia

Kim, Ji Sun; Kwon, Young Joon; Lee, Hwa Young; Lee, Ho-Sung; Kim, Sungkean; Shim, Se-Hoon

doi:10.9758/cpn.2020.18.1.127

Cited by 17 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other variables such as neurophysiological (MMN) parameters except for dMMN amplitude, various clinical variables (age, medication, illness duration, DUP, and PANSS score), and cognitive and social functions (BACS, mGAF, SCoRS, and JART IQ scores) did not contribute to the prediction. This was an unexpected finding because previous studies have demonstrated that predictors of treatment response and long-term outcome in schizophrenia included these factors (6,11), especially DUP (4,5). However, the present results may be partly consistent with our previous reports that changes in ERPs including MMN were observed prior to changes in neuropsychological test results (56,57).…”

Section: Discussionsupporting

confidence: 91%

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients

et al. 2021

View full text Add to dashboard Cite

Objective: Remission in schizophrenia patients is associated with neurocognitive, social, and role functioning during both the early and chronic stages of schizophrenia. It is well-established that the amplitudes of duration mismatch negativity (dMMN) and frequency MMN (fMMN) are reduced in schizophrenia patients. However, the potential link between MMN and remission has not been established. In this study, we investigated the relationship between MMNs and remission in first-episode schizophrenia (FES) and their association with neurocognitive and social functioning.Method: dMMN and fMMN were measured in 30 patients with FES and 22 healthy controls at baseline and after a mean of 3 years. Clinical symptoms and cognitive and social functioning in the patients were assessed at the time of MMN measurements by using the Positive and Negative Syndrome Scale (PANSS), modified Global Assessment of Functioning (mGAF), Schizophrenia Cognition Rating Scale (SCoRS), and the Brief Assessment of Cognition in Schizophrenia (BACS). Remission of the patients was defined using the criteria by the Remission in Schizophrenia Working Group; of the 30 patients with FES, 14 achieved remission and 16 did not.Results: Baseline dMMN amplitude was reduced in FES compared to healthy controls. Further, baseline dMMN in the non-remitters had decreased amplitude and prolonged latency compared to the remitters. MMN did not change during follow-up period regardless of parameters, diagnosis, or remission status. Baseline dMMN amplitude in FES was correlated with future SCoRS and PANSS total scores. Logistic regression analysis revealed that dMMN amplitude at baseline was a significant predictor of remission.Conclusions: Our findings suggest that dMMN amplitude may be a useful biomarker for predicting symptomatic remission and improvement of cognitive and social functions in FES.

show abstract

Section: Discussionsupporting

confidence: 91%

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…P300 is not a unitary phenomenon, but it is composed of 2 functionally different subcomponents: an early component, the P3a, which usually peaks within a time window of 130–275 ms after the stimulus onset, that reflects an involuntary shift in attention toward a deviant stimulus; a later component, the P3b, observed within a time window of 275–600 ms after the stimulus, that reflects a conscious and controlled attentive process toward a stimulus and its task-relevance ( 60 ). Some studies explicitly differentiated P3a and P3b, analyzing one or both subcomponents in the same sample, while others referred more generally to P300 recordings.…”

Section: Resultsmentioning

confidence: 99%

“…A vast EEG literature has documented different abnormalities of neuronal activity in subjects with chronic SCZ, as compared to healthy controls (HCs) ( 29 , 33 , 43 – 49 ). In particular, several studies have consistently reported alterations in the activity of the whole spectrum of frequency bands ( 49 – 53 ), changes in MSs topography and/or other parameters ( 46 , 47 , 54 ) and a reduction of amplitude in ERPs, such as N100 ( 55 – 58 ), mismatch negativity (MMN) ( 59 , 60 ), and P300 ( 33 , 57 , 61 ). Furthermore, these alterations have been related to the severity of symptoms, as well as cognitive and functional impairment in schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, these alterations have been related to the severity of symptoms, as well as cognitive and functional impairment in schizophrenia. For instance, aberrant frequency bands activity has been associated to cognitive deficits and positive and negative symptoms ( 50 – 53 ); alterations in MS parameters to negative symptoms, hallucinations, and duration of illness ( 46 , 47 , 54 ); reductions in N100 amplitude to auditory hallucinations and attention deficits ( 55 , 57 , 58 ); deficits in MMN to positive symptoms and functioning impairment ( 57 , 59 , 60 ); P300 to neurocognitive impairments and negative symptoms ( 57 , 61 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Introduction: Electrophysiological (EEG) abnormalities in subjects with schizophrenia have been largely reported. In the last decades, research has shifted to the identification of electrophysiological alterations in the prodromal and early phases of the disorder, focusing on the prediction of clinical and functional outcome. The identification of neuronal aberrations in subjects with a first episode of psychosis (FEP) and in those at ultra high-risk (UHR) or clinical high-risk (CHR) to develop a psychosis is crucial to implement adequate interventions, reduce the rate of transition to psychosis, as well as the risk of irreversible functioning impairment. The aim of the review is to provide an up-to-date synthesis of the electrophysiological findings in the at-risk mental state and early stages of schizophrenia.Methods: A systematic review of English articles using Pubmed, Scopus, and PsychINFO was undertaken in July 2020. Additional studies were identified by hand-search. Electrophysiological studies that included at least one group of FEP or subjects at risk to develop psychosis, compared to healthy controls (HCs), were considered. The heterogeneity of the studies prevented a quantitative synthesis.Results: Out of 319 records screened, 133 studies were included in a final qualitative synthesis. Included studies were mainly carried out using frequency analysis, microstates and event-related potentials. The most common findings included an increase in delta and gamma power, an impairment in sensory gating assessed through P50 and N100 and a reduction of Mismatch Negativity and P300 amplitude in at-risk mental state and early stages of schizophrenia. Progressive changes in some of these electrophysiological measures were associated with transition to psychosis and disease course. Heterogeneous data have been reported for indices evaluating synchrony, connectivity, and evoked-responses in different frequency bands.Conclusions: Multiple EEG-indices were altered during at-risk mental state and early stages of schizophrenia, supporting the hypothesis that cerebral network dysfunctions appear already before the onset of the disorder. Some of these alterations demonstrated association with transition to psychosis or poor functional outcome. However, heterogeneity in subjects' inclusion criteria, clinical measures and electrophysiological methods prevents drawing solid conclusions. Large prospective studies are needed to consolidate findings concerning electrophysiological markers of clinical and functional outcome.

show abstract

“…All data were processed with a 0.1–100 Hz band-pass filter and sampled at 1000 Hz. The EEG acquisition procedure was described in our previous study 74 , 75 .…”

Section: Methodsmentioning

confidence: 99%

Auditory evoked potentials and suicidal behaviors in patients with major depressive disorders

Kim

Lee

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Loudness dependence of auditory evoked potentials (LDAEP) has been proposed as a biological marker of central serotonergic activity related to suicides. This study’s objective was to analyze the difference in LDAEP between depressed patients with suicide attempts (SA) and suicidal ideation (SI). It included 130 participants (45 depressed patients with SA, 49 depressed patients with SI, and 36 healthy controls) aged > 18 years who exhibited LDAEP during electroencephalography. Psychological characteristics and event-related potentials of the three groups were compared. There was no significant difference in LDAEP between major depressive disorder (MDD) patients with SA and SI (p = 0.59). MDD patients with SI, who attempted suicide had significantly lower LDAEP than healthy controls (p = 0.01 and p = 0.01, respectively). However, the significance disappeared when psychological characteristics were controlled. Our results suggest that LDAEP might not be possible biomarkers for suicidal behaviors in patients with MDD. Further studies to assess the biological basis of suicide and identify the underlying dimensions that mediate the relationship between the biological basis and suicidal behaviors will be needed.

show abstract

Mismatch Negativity Indices as a Prognostic Factor for Remission in Schizophrenia

Cited by 17 publications

References 41 publications

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients

Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients

EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review

Auditory evoked potentials and suicidal behaviors in patients with major depressive disorders

Contact Info

Product

Resources

About